Related Experiment Video
Updated: Jan 24, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Molecular imaging and therapy of somatostatin receptor positive tumors
Jana Ivanidze1, Michelle Roytman1, Arielle Sasson2
1New York-Presbyterian Hospital/Weill Cornell Medical Center, United States of America.
Abstract:
Somatostatin receptors (SSTR) are upregulated in the cells of origin that define numerous neuroendocrine neoplasms. PET imaging with 68Ga-DOTATATE allows specific targeting of SSTR2A, a single species of SSTR receptor, which is commonly overexpressed in a variety of gastroenteropancreatic neuroendocrine tumors, as well as pulmonary carcinoid and head and neck tumors. Due to more specific targeting of SSTR2 as well as lower radiation dose, shorter study length, ability to quantify uptake, and lower cost, 68Ga-DOTATATE has demonstrated superior imaging attributes when compared to 111In-pentetreotide. As with any novel imaging modality, dedicated training, increasing experience and staying up-to-date with scientific publications are required to provide optimal patient care. The purpose of this review is to summarize the current state of the art in SSTR-targeted molecular imaging and discuss ongoing and future potential diagnostic and therapeutic applications.
Insights
Gallium-68 DOTATATE PET imaging targets somatostatin receptors (SSTR) in neuroendocrine neoplasms. This method offers superior diagnostic attributes compared to older imaging agents, enabling better patient care and potential therapeutic applications.
Area of Science:
- Molecular imaging
- Nuclear medicine
- Oncology
Background:
- Somatostatin receptors (SSTR) are frequently overexpressed in neuroendocrine neoplasms.
- SSTR-targeted molecular imaging is crucial for diagnosing and managing these tumors.
Purpose of the Study:
- To review the current advancements in SSTR-targeted molecular imaging.
- To discuss the diagnostic and therapeutic potential of these imaging techniques.
Main Methods:
- Positron Emission Tomography (PET) imaging using 68Ga-DOTATATE.
- Targeting of Somatostatin Receptor subtype 2A (SSTR2A), commonly overexpressed in neuroendocrine tumors.
- Comparison with older imaging agents like 111In-pentetreotide.
Main Results:
- 68Ga-DOTATATE demonstrates superior imaging attributes, including specific SSTR2 targeting.
- Advantages include lower radiation dose, shorter study duration, quantifiable uptake, and reduced cost.
- 68Ga-DOTATATE shows improved performance over 111In-pentetreotide for neuroendocrine tumor imaging.
Conclusions:
- 68Ga-DOTATATE PET imaging represents a significant advancement in SSTR-targeted molecular imaging.
- Optimal patient care requires dedicated training and staying updated with scientific literature.
- Ongoing research explores further diagnostic and therapeutic applications in neuroendocrine neoplasms.
More Related Videos
11:09Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
Published on: July 13, 2010
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Related Concept Videos
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Position-effect Variegation
Internal Receptors
Serial Position Effect
Molecular Models
Gene Therapy